Grace Therapeutics

Yahoo Finance • 3 days ago

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by Data from Phase 3 STR... Full story

Yahoo Finance • 2 months ago

Grace Therapeutics GAAP EPS of -$0.79

* Grace Therapeutics press release [https://seekingalpha.com/pr/20144037-grace-therapeutics-announces-2025-fiscal-year-end-results-provides-business-update] (NASDAQ:GRCE [https://seekingalpha.com/symbol/GRCE]): FY GAAP EPS of -$0.79. *... Full story

Yahoo Finance • 2 months ago

Grace Therapeutics to Participate in the 2025 BIO International Conference

PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodip... Full story

Yahoo Finance • 6 months ago

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million in upfront gross proceeds with the potential to receive up to an additional $15 mill... Full story

Yahoo Finance • 6 months ago

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRINCETON, N.J., Feb. 10, 2025 (GLOBE... Full story